| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Société des Industries Pharmaceutiques de Tunisie - S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | د.ت5.50 |
| 52 Week High | د.ت6.00 |
| 52 Week Low | د.ت3.75 |
| Beta | 0 |
| 11 Month Change | -4.01% |
| 3 Month Change | 15.79% |
| 1 Year Change | n/a |
| 33 Year Change | -1.79% |
| 5 Year Change | 27.91% |
| Change since IPO | -69.43% |
Recent News & Updates
Recent updates
Shareholder Returns
| SIPHA | TN Pharmaceuticals | TN Market | |
|---|---|---|---|
| 7D | 0% | -2.9% | -0.6% |
| 1Y | n/a | 3.9% | 11.0% |
Return vs Industry: Insufficient data to determine how SIPHA performed against the TN Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how SIPHA performed against the TN Market.
Price Volatility
| SIPHA volatility | |
|---|---|
| SIPHA Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.4% |
| Market Average Movement | 2.9% |
| 10% most volatile stocks in TN Market | 4.7% |
| 10% least volatile stocks in TN Market | 1.7% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine SIPHA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | n/a | Anis Klouz | www.siphat.rns.tn |
Société des Industries Pharmaceutiques de Tunisie - S.A. engages in the research, development, manufacture, packaging, and marketing of pharmaceutical products for human use in Tunisia and internationally. It provides rheumatology drugs, such as MYORELAX, NIFLUMIC, and ALGESAL SURACTIVE; stomatology drugs, including HEXABAIN; and ANALGAN CODEINE 300mg/25mg indicated for the symptomatic treatment of moderate and intense pain. The company was founded in 1989 and is headquartered in Ben Arous, Tunisia.
Société des Industries Pharmaceutiques de Tunisie - S.A. Fundamentals Summary
| SIPHA fundamental statistics | |
|---|---|
| Market cap | د.ت9.90m |
| Earnings (TTM) | -د.ت17.10m |
| Revenue (TTM) | د.ت20.23m |
0.0x
P/S Ratio0.0x
P/E RatioIs SIPHA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SIPHA income statement (TTM) | |
|---|---|
| Revenue | د.ت20.23m |
| Cost of Revenue | د.ت11.03m |
| Gross Profit | د.ت9.19m |
| Other Expenses | د.ت26.30m |
| Earnings | -د.ت17.10m |
Last Reported Earnings
Jun 30, 2020
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did SIPHA perform over the long term?
See historical performance and comparison